[The mouse as preclinical models of lung cancer]

Area of Science:

• Oncology
• Translational Medicine
• Genomics

Background:

• Lung cancer poses a significant global health challenge with a poor prognosis for many patients.
• Current targeted therapies benefit only a subset of lung cancer patients (approx. 20%) with specific mutations like EGFR, ALK, or HER2.
• Many oncogenic mutations, such as KRas, currently lack validated targeted treatment options.

Purpose of the Study:

• To review various mouse models of lung carcinoma.
• To illustrate the utility of these models in identifying and validating novel therapeutic targets.
• To explore their application in studying acquired resistance mechanisms and testing new therapeutic strategies.

Main Methods:

• Comprehensive review of existing literature on lung carcinoma mouse models.
• Analysis of the role of these models in drug discovery and development pipelines.
• Evaluation of their use in preclinical testing and therapeutic strategy validation.

Main Results:

• Mouse models are instrumental in discovering and validating new therapeutic targets for lung cancer.
• These models facilitate the study of mechanisms underlying secondary resistance to targeted therapies.
• They serve as essential preclinical platforms for evaluating the efficacy of novel therapeutic strategies.

Conclusions:

• Mouse models are indispensable tools in lung cancer research, bridging basic science and clinical application.
• Their application accelerates the development of targeted therapies for previously untreatable mutations.
• Continued use of mouse models is vital for advancing lung cancer treatment and improving patient survival rates.